Trial watch: Phase III and submission failures: 2007–2010

@article{Arrowsmith2011TrialWP,
  title={Trial watch: Phase III and submission failures: 2007–2010},
  author={John Edmund Arrowsmith},
  journal={Nature Reviews Drug Discovery},
  year={2011},
  volume={10},
  pages={87-87}
}
  • J. Arrowsmith
  • Published 1 February 2011
  • Medicine
  • Nature Reviews Drug Discovery

Figures and Topics from this paper

Innovación tecnológica y financiación de prestaciones
    La aparición de numerosas y variadas nuevas tecnologías con novedosos mecanismos de acción bajo un patrón de innovación incremental demanda una reforma estructural profunda de la regulación de
Can animal data translate to innovations necessary for a new era of patient-centred and individualised healthcare? Bias in preclinical animal research
TLDR
Bias in animal research needs to be addressed before medical research and healthcare decision-making can be more evidence-based and proposals need development through open debate and subsequent rigorous implementation so that reviewers may determine the value of animal research to human health.
The Ethical Implications for Humans in Light of the Poor Predictive Value of Animal Models
The notion that animals could be used as predictive models in science has been influenced by relatively recent developments in the fields of complexity science, evolutionary and developmental
Why is publication of negative clinical trial data important?
TLDR
The impact of reducing failure in clinical trials should be greater than reducing failure at all points along the drug discovery and development process, as this is where the most spend occurs.
An Effector Index to Predict Target Genes at GWAS Loci
TLDR
This work outlines a simple, understandable approach to prioritize genes at GWAS loci for functional follow-up and drug development, and provides a systematic strategy for prioritization of GWAS target genes.
Drug Repurposing: A Review
The drug development is a very time consuming and complex process. Drug development Process is Expensive. Success rate for the new drug development is very small. In recent years, decreases the new
Drug repurposing against breast cancer by integrating drug-exposure expression profiles and drug–drug links based on graph neural network
TLDR
By extracting the drug signatures and topological structure information contained in the drug relationships, GraphRepur can predict new drugs for breast cancer, outperforming previous state-of-the-art approaches and some classic machine learning methods.
Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review
TLDR
The objective of this study was to determine the frequency with which early-phase clinical trials are used as the primary source of evidence in the submission for reimbursement to the pan-Canadian Oncology Drug Review (pCODR).
...
1
2
3
4
5
...